GHK-Cu is nearly always framed as something that builds: more collagen, better repair, faster healing. There is a smaller strand of its research pointing the other way, at restraining a repair signal rather than amplifying it, and it is the strand relevant to scarring. It is also a good example of a study whose most important detail is buried in the control group.
This article covers GHK-Cu as a cosmetic ingredient. It is not medical advice, and nothing here has been evaluated by the FDA.
Key Takeaways
- In a 2014 study, cultured normal human dermal fibroblasts were stimulated with IGF-2 to drive TGF-beta1 secretion, then treated with 1 nM solutions of GHK, GHK-Cu, or copper chloride [1].
- IGF-2 significantly increased TGF-beta1 secretion, and GHK, its copper complex, and free copper ions all decreased that IGF-2-dependent secretion [1].
- The authors connected this to the potential use of the peptide in cosmetics to treat and prevent hypertrophic scars, since TGF-beta1 is central to fibrosis and scar tissue formation [1].
- The detail that constrains the result: copper chloride produced the same directional effect, so nothing here is specific to the peptide complex [1].
- This is one cell-culture study at a single concentration. No human trial has tested GHK-Cu for hypertrophic scars or keloids.
Why TGF-beta1 Is the Molecule to Watch for Scarring
Wound repair is a balance. Too little fibrotic response and wounds do not close properly. Too much and you get raised, thickened scar tissue: hypertrophic scars, and in the more extreme case keloids, which extend beyond the original wound boundary.
TGF-beta1 sits close to the centre of that balance. It is involved in cell growth, differentiation, proliferation, apoptosis, and immune regulation, and it is one of the signals driving fibroblasts toward producing matrix during repair. Excess TGF-beta1 activity is a recurring theme in fibrosis research generally, not just in skin. Anything that reduces TGF-beta1 secretion in fibroblasts is therefore worth a look from a scarring perspective.
What the Experiment Measured
The design was direct [1]. Normal human dermal fibroblasts were cultured, and IGF-2 at 100 ng/mL was used to stimulate TGF-beta1 secretion, which it did significantly. Against that stimulated baseline, the researchers applied 1 nM solutions of three things: GHK, GHK-Cu, and copper chloride. Total TGF-beta1 protein was measured by ELISA, with total cellular protein quantified separately so results could be normalised.
All three treatments decreased the IGF-2-dependent TGF-beta1 secretion. The authors presented this as new information on the potential use of the peptide in cosmetics for treating and preventing hypertrophic scars.
The Control Group Is the Interesting Part
Copper chloride, plain copper salt with no peptide involved, reduced the secretion too.
That single fact does more to shape how this study should be read than the headline result does. If free copper ions reproduce the effect, the experiment has not demonstrated that anything about the GHK-Cu complex specifically is responsible. It may simply be showing what copper does to this pathway in this cell system.
This is not a flaw in the study. Including the copper salt is exactly the right control to run, and reporting that it worked too is the researchers being straightforward. It is a flaw in how such findings usually get repeated, where the copper control silently disappears and the result becomes a claim about copper peptides.
How Far This Is From a Clinical Claim
Several gaps sit between this experiment and any statement about scars on a person.
It is cell culture. Fibroblasts in a plate, stimulated artificially with IGF-2, are a model of one interaction, not a model of a healing wound with its full cast of cell types, immune signalling, and mechanical tension, which is itself a major driver of hypertrophic scarring.
It is one concentration. A 1 nM solution applied directly to cells says nothing about what concentration reaches dermal fibroblasts from a topical product, a question GHK-Cu’s own literature treats as genuinely unresolved given the complex’s formulation and delivery difficulties [2].
It is a single study from 2014, and it has not been followed by human trials on scarring. The same research group has published related fibroblast work, including on how GHK and its copper complexes affect TNF-alpha-dependent IL-6 secretion [3], which is consistent with an anti-inflammatory profile in culture but is the same class of evidence rather than a step up from it.
Where It Fits in the Wider Picture
Read alongside GHK-Cu’s broader gene-expression literature, which describes wide-ranging effects on remodelling and repair pathways [4], the TGF-beta1 result is coherent rather than surprising. A molecule described as modulating repair should be expected to restrain some signals as well as promote others; a purely amplifying agent would be a worse candidate for scar-sensitive situations, not a better one.
That coherence is a reason the question deserves proper study. It is not a reason to treat the question as answered.
The Practical Position
If you have keloids or hypertrophic scarring, this is not a treatment. Those conditions have real dermatological management, including intralesional corticosteroids, silicone-based approaches, pressure therapy, and procedural options, and they are managed by clinicians because the treatment choice depends on the scar and the person. A cosmetic serum with cell-culture evidence does not belong in that decision.
If you are using GHK-Cu generally and wondered whether it might make scarring worse by driving collagen production, this study is mildly reassuring in the opposite direction, though a single fibroblast experiment is thin ground for reassurance in either direction.
The accurate summary is that GHK-Cu has a plausible and under-investigated connection to scar biology, one small in vitro study pointing at it, and a control group in that same study that limits how much weight the peptide itself can carry.
Frequently Asked Questions
Can GHK-Cu prevent keloids?
There is no human evidence for that. The relevant research is a cell-culture study showing GHK and GHK-Cu reduced IGF-2-driven TGF-beta1 secretion in fibroblasts [1]. Keloids are a clinical problem with established dermatological treatments, and a cell result is not a substitute for them.
Is there human evidence for GHK-Cu on hypertrophic scars?
No published human trial has tested it for that. The authors of the fibroblast study raised hypertrophic scar prevention as a potential application of their finding [1], which is a proposal for future work rather than a result.
Why does it matter that copper chloride did the same thing?
Because it means the experiment did not isolate an effect unique to the peptide complex. GHK, GHK-Cu, and free copper ions all reduced the secretion [1]. If plain copper reproduces the effect in culture, the result is weaker support for the specific complex than it first appears.
Does GHK-Cu help scars that are already old?
Nothing in this line of research addresses mature scars. TGF-beta1 signalling is most relevant while a scar is actively forming. An established, settled scar is a different situation, and it is one where procedural options handled by a dermatologist have actual evidence behind them.
How is this different from GHK-Cu for acne scars?
Post-inflammatory marks from acne are largely a pigment and texture issue in already-healed skin. Hypertrophic scars and keloids are excess fibrous tissue from an over-active repair response. They are different biological problems even though both get called scars.
References
- Gruchlik A, Chodurek E, Dzierzewicz Z. Effect of Gly-His-Lys and Its Copper Complex on TGF-beta Secretion in Normal Human Dermal Fibroblasts. Acta Poloniae Pharmaceutica (2014). PMID 25745767
- Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically Applied GHK as an Anti-Wrinkle Peptide: Advantages, Problems and Prospective. BioImpacts (2025). PMID 39963574
- Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and Their Copper Complexes on TNF-alpha-Dependent IL-6 Secretion in Normal Human Dermal Fibroblasts. Acta Poloniae Pharmaceutica (2012). PMID 23285694
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences (2018). PMID 29986520 (authors affiliated with Skin Biology, a company that sells copper-peptide products)
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical or dermatological advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
